About A-Alpha Bio
A-Alpha Bio is a company based in Seattle (United States) founded in 2017. A-Alpha Bio has raised $45.24 million across 10 funding rounds from investors including Gates Foundation, Xontogeny and U.S. Department of Defense. The company has 48 employees as of December 31, 2024. A-Alpha Bio offers products and services including AlphaSeq and AlphaBind. A-Alpha Bio operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter Seattle, United States
- Employees 48 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name A-Alpha Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$45.24 M (USD)
in 10 rounds
-
Latest Funding Round
$14.5 M (USD), Grant
May 21, 2024
-
Investors
Gates Foundation
& 12 more
-
Employee Count
48
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of A-Alpha Bio
A-Alpha Bio offers a comprehensive portfolio of products and services, including AlphaSeq and AlphaBind.
Platform for quantitative measurement of protein-protein interactions.
Tool for predicting protein binding from sequence data.
People of A-Alpha Bio
Unlock access to complete
Unlock access to complete
Funding Insights of A-Alpha Bio
A-Alpha Bio has successfully raised a total of $45.24M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $14.5 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in A-Alpha Bio
A-Alpha Bio has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Xontogeny and U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in science-driven companies are made.
|
Locked | Locked | Locked | |
|
Life science startups are accelerated through focused programs by Xontogeny.
|
Locked | Locked | Locked | |
|
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond.
|
Locked | Locked | Locked |
Investor details for A-Alpha Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by A-Alpha Bio
Investment portfolio details for A-Alpha Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - A-Alpha Bio
Detailed financials for A-Alpha Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
A-Alpha Bio Comparisons
Peer comparison for A-Alpha Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of A-Alpha Bio
A-Alpha Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Digital platform transforming the delivery of biologic medicines
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
Detailed competitors of A-Alpha Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on A-Alpha Bio
Complete news archive for A-Alpha Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about A-Alpha Bio
A-Alpha Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
A-Alpha Bio is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
A-Alpha Bio is a funded company, having raised a total of $45.24M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at A-Alpha Bio is 48.
A-Alpha Bio was founded in 2017 in Seattle, United States, within the biotechnology sector. A cell-based platform technology is provided by the company, utilizing engineered yeast cells to measure protein interactions. These tools support drug development processes by quantifying interaction dynamics. Operations focus on advancing research applications in protein biology, with services centered on precise measurement methodologies for pharmaceutical innovation.
A-Alpha Bio's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
A-Alpha Bio offers AlphaSeq and AlphaBind.
A-Alpha Bio has 13 investors. Key investors include Gates Foundation, Xontogeny, U.S. Department of Defense, Breakout Ventures, and Madrona.